Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline • Scleroderma disease overview • Market landscape • Market overview • Five forces analysis PART 05: Pipeline landscape PART 06: Market segmentation by drug class • Anti-inflammatory drugs • Immunosuppressants • Others • PDE5 inhibitors • Calcium channel blockers PART 07: Geographical segmentation • Scleroderma treatment market in Americas • Scleroderma treatment market in EMEA • Scleroderma treatment market in APAC PART 08: Decision framework PART 09: Drivers and challenges • Market drivers • Market challenges PART 10: Market trends • Partnerships and strategic alliances • Introduction of stem cells in scleroderma treatment • Advent of novel therapies PART 11: Vendor landscape • Competitive scenario PART 12: Key vendor analysis • AstraZeneca • F. Hoffmann-La Roche • GlaxoSmithKline • Pfizer • Other prominent vendors PART 13: Appendix • List of abbreviations List of Exhibits Exhibit 01: Types of scleroderma Exhibit 02: Global scleroderma treatment market snapshot Exhibit 03: Global scleroderma treatment market 2016-2021 ($ millions) Exhibit 04: Opportunity analysis in global scleroderma treatment market Exhibit 05: Five forces analysis Exhibit 06: Number of pipeline molecules by vendors at various phases Exhibit 07: Key clinical trials Exhibit 08: Global scleroderma treatment market by drug class Exhibit 09: Side effects associated with anti-inflammatory drug class Exhibit 10: Global scleroderma anti-inflammatory drugs market 2016-2021 ($ millions) Exhibit 11: Drivers and challenges of anti-inflammatory drugs Exhibit 12: Side effects associated with immunosuppressants Exhibit 13: Global scleroderma immunosuppressants market 2016-2021 ($ millions) Exhibit 14: Drivers and challenges of immunosuppressants Exhibit 15: Global scleroderma treatment market by others drug class 2016-2021 ($ millions) Exhibit 16: Major drug classes included in the others segment Exhibit 17: Side effects associated with PDE5 inhibitors Exhibit 18: Global scleroderma PDE5 inhibitors market 2016-2021 ($ millions) Exhibit 19: Drivers and challenges of PDE5 inhibitors Exhibit 20: Side effects associated with calcium channel blockers Exhibit 21: Global scleroderma calcium channel blockers market 2016-2021 ($ millions) Exhibit 22: Drivers and challenges of calcium channel blockers Exhibit 23: Global scleroderma treatment market segmentation based on geography 2016 and 2021 (%) Exhibit 24: Global scleroderma treatment market revenue by geography 2016-2021 ($ millions) Exhibit 25: Market scenario in Americas Exhibit 26: Scleroderma treatment market in Americas 2016-2021 ($ millions) Exhibit 27: Market scenario in EMEA Exhibit 28: Scleroderma treatment market in EMEA 2016-2021 ($ millions) Exhibit 29: Market scenario in APAC Exhibit 30: Scleroderma treatment market in APAC 2016-2021 ($ millions) Exhibit 31: Promising new projects in scleroderma studies Exhibit 32: Potential therapeutic targets involved in numerous studies for scleroderma Exhibit 33: Strategic success factors of companies in global scleroderma treatment market Exhibit 34: AstraZeneca: Key highlights Exhibit 35: AstraZeneca: Strength assessment Exhibit 36: AstraZeneca: Strategy assessment Exhibit 37: AstraZeneca: Opportunity assessment Exhibit 38: F. Hoffmann-La Roche: Key highlights Exhibit 39: F. Hoffmann-La Roche: Strength assessment Exhibit 40: F. Hoffmann-La Roche: Strategy assessment Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment Exhibit 42: GlaxoSmithKline: Key highlights Exhibit 43: GlaxoSmithKline: Strength assessment Exhibit 44: GlaxoSmithKline: Strategy assessment Exhibit 45: GlaxoSmithKline: Opportunity assessment Exhibit 46: Pfizer: Key highlights Exhibit 47: Pfizer: Strength assessment Exhibit 48: Pfizer: Strategy assessment Exhibit 49: Pfizer: Opportunity assessment